This is a summary of the European public assessment report (EPAR) for Telmisartan Teva Pharma. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Telmisartan Teva Pharma.
Therapeutic Indication
### Therapeutic indication Treatment of essential hypertension in adults.
Therapeutic Area (MeSH)
ATC Code
C09CA07
ATC Item
telmisartan
Pharmacotherapeutic Group
Agents acting on the renin-angiotensin system
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Telmisartan | N/A | 替米沙坦 |
EMA Name
Telmisartan Teva Pharma
Medicine Name
Telmisartan Teva Pharma
Aliases
N/ANo risk management plan link.
